Omalizumab (Xolair) is a medicine approved by the U.S. Food
and Drug Administration (FDA) for use in people age 12 and older who have moderate
or severe persistent
asthma. It should be used only after first-line
treatments (such as corticosteroids and long-acting beta2-agonists) have
failed. Omalizumab is much more expensive than any of the conventional
treatments for asthma. And its role in asthma treatment is not clear.
Omalizumab works by blocking immunoglobulin E (IgE) from attaching to
allergens. When IgE attaches to an allergen, it sets
off a process that eventually leads to the symptoms of an
If your child has been diagnosed with asthma, you know the difficulty of managing your child’s asthma symptoms at school. Many children with asthma have symptoms at school. That’s why it's important to get the school involved in managing your child’s asthma, so a responsible adult at the school knows when and how to administer asthma inhalers or other asthma treatment. Even if your child has mild asthma, working with the classroom teacher and other school officials is vital for managing your...
Initial studies show
that omalizumab reduces asthma episodes, improves
peak expiratory flow (PEF), reduces the need for other
medicines, and reduces emergency room visits and hospitalization.1 But it has been studied only in people with positive skin
tests to indoor allergens such as
animal dander, cockroaches, and molds.
Omalizumab is injected, and the dose is determined by a person's body
weight and IgE level.
Omalizumab appears to be effective in people
Have had a positive skin or blood test for a specific
Have blood levels of immunoglobulin E between 30 and 700
IU per milliliter.
Omalizumab can be considered in people who meet the above
criteria and whose asthma is not well controlled after using inhaled
corticosteroids and long-acting beta2-agonists or
leukotriene pathway modifiers for 3 months. People who use oral or injected
(systemic) corticosteroids or who require high doses of inhaled corticosteroids
for daily control can also consider using omalizumab.
allergic reactions, including
anaphylaxis, are possible when taking omalizumab,
but this is rare. So people who get omalizumab are watched for 2 hours
after they receive their first 2 doses. They should also carry epinephrine
(EpiPen) in case they have an allergic reaction after omalizumab
In this article
This information is produced and provided by the National
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Institute via the Internet web site at http://
.gov or call 1-800-4-CANCER.
WebMD Medical Reference from Healthwise
February 22, 2013
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this